Cambrex Corporation (NYSE: CBM) is a custom development and manufacturing organization that specializes in products and services that accelerate the development and commercialization of small molecule therapeutics. While the stock has risen some 34% year to date, the company's discounted valuation and upcoming catalysts could suggest greater upside ahead. In this article, we will take a look at both of these drivers in greater detail.
A Brief Primer
Cambrex generates the majority of its revenues from custom development and manufacturing (45%), with generics (36%), control substances (14%) and drug delivery (5%) rounding out its business. With R&D and cGMP manufacturing facilities in the U.S., Europe and India, the company provides APIs, advanced intermediates, drug delivery products and custom development...
Only subscribers can access this article, which is part of the PRO research library covering 3,587 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: